Brought to you by 
Bayer Completes its Acquisition of Vividion Therapeutics for a Total Consideration of $2B
30 Sep 2021
Executive Summary
Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (a privately held biopharmaceutical company utilizing novel discovery technologies to unlock undruggable targets with precision therapeutics) for a total consideration of $2B. The closing of the transaction is expected to take place in Q3 2021.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer Completes its Acquisition of Vividion Therapeutics for a Total Consideration of $2B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice